Published in Viral Immunol on June 01, 2010
Flavivirus-induced antibody cross-reactivity. J Gen Virol (2011) 1.28
Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin (2011) 1.24
Analysis of T cell responses to the major allergens from German cockroach: epitope specificity and relationship to IgE production. J Immunol (2012) 1.24
A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One (2012) 1.20
T cell responses to known allergen proteins are differently polarized and account for a variable fraction of total response to allergen extracts. J Immunol (2012) 1.19
Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol (2012) 1.17
B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. J Virol (2016) 1.00
Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe. PLoS One (2013) 0.82
Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis (2013) 0.80
Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes. Clin Exp Immunol (2014) 0.79
Meta-Analysis of Dengue Severity during Infection by Different Dengue Virus Serotypes in Primary and Secondary Infections. PLoS One (2016) 0.78
Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. Emerg Microbes Infect (2017) 0.77
NIAID workshop on Flavivirus immunity. Viral Immunol (2010) 0.76
T cell epitope mapping of the e-protein of West Nile virus in BALB/c mice. PLoS One (2014) 0.76
A comparison of epitope repertoires associated with myasthenia gravis in humans and nonhuman hosts. Autoimmune Dis (2012) 0.75
Reproducibility and conflicts in immune epitope data. Immunology (2016) 0.75
Insight into SNPs and epitopes of E protein of newly emerged genotype-I isolates of JEV from Midnapur, West Bengal, India. BMC Immunol (2017) 0.75
Experimental inoculation of Artibeus jamaicensis bats with dengue virus serotypes 1 or 4 showed no evidence of sustained replication. Am J Trop Med Hyg (2014) 0.75
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 6.25
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res (2003) 4.90
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
Dengue virus structural differences that correlate with pathogenesis. J Virol (1999) 4.26
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med (2006) 4.23
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05
Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet (1999) 3.97
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis (2003) 3.52
Pathogenic flaviviruses. Lancet (2008) 3.34
Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol (2000) 3.21
Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol (2006) 3.07
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol (2004) 2.83
Dengue: defining protective versus pathologic immunity. J Clin Invest (2004) 2.73
Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A (2007) 2.67
Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol (1985) 2.63
Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol (2009) 2.57
Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol (2005) 2.50
Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis (1973) 2.48
Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol (1990) 2.47
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Yellow fever: a decade of reemergence. JAMA (1996) 2.44
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ (1981) 2.36
Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol (2006) 2.33
Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev (2008) 2.19
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Yellow fever vaccine. Expert Rev Vaccines (2005) 2.13
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect (2006) 2.06
IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J Immunol (2003) 2.03
T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol (2006) 2.02
The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol (2006) 1.93
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis (2001) 1.90
Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol (1998) 1.90
Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis (2001) 1.84
Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis (2001) 1.79
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol (1986) 1.67
Immunoassay targeting nonstructural protein 5 to differentiate West Nile virus infection from dengue and St. Louis encephalitis virus infections and from flavivirus vaccination. J Clin Microbiol (2003) 1.65
Dengue virus evolution and virulence models. Clin Infect Dis (2007) 1.64
T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol (2002) 1.62
Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol (2005) 1.60
Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol (2006) 1.57
Mouse models of dengue virus infection and disease. Antiviral Res (2008) 1.56
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 1.55
Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am J Trop Med Hyg (1991) 1.54
An analysis of the epitope knowledge related to Mycobacteria. Immunome Res (2007) 1.53
Dengue virus-specific, human CD4+ CD8- cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones. J Virol (1991) 1.52
Immunopathology of flavivirus infections. Immunol Cell Biol (2006) 1.52
Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis (1974) 1.51
Laboratory findings in tick-borne encephalitis--correlation with clinical outcome. Infection (2000) 1.46
Synthetic peptides derived from the deduced amino acid sequence of the E-glycoprotein of Murray Valley encephalitis virus elicit antiviral antibody. Virology (1989) 1.42
Immunology and immunopathogenesis of dengue disease. Adv Virus Res (2003) 1.41
Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol (1990) 1.40
Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest (1996) 1.35
Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis (2002) 1.34
Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol (2009) 1.30
Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology (2002) 1.28
The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants. Virology (1994) 1.27
Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol (2007) 1.24
Human Dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol (2000) 1.23
Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol (1996) 1.22
Topographical analysis of antigenic determinants on envelope glycoprotein V3 (E) of Japanese encephalitis virus, using monoclonal antibodies. J Virol (1983) 1.21
Cross-reactivity in flavivirus serology: new implications of an old finding? Med Microbiol Immunol (2002) 1.21
Immune response to synthetic peptides of dengue prM protein. Vaccine (2002) 1.19
Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol (1989) 1.14
Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol (1986) 1.13
Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. Clin Vaccine Immunol (2007) 1.13
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Recognition of synthetic oligopeptides from nonstructural proteins NS1 and NS3 of dengue-4 virus by sera from dengue virus-infected children. Am J Trop Med Hyg (1997) 1.12
The enigma of yellow fever in East Africa. Rev Med Virol (2008) 1.09
A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol (2007) 1.07
Cross-reactive T-cell responses to the nonstructural regions of dengue viruses among dengue fever and dengue hemorrhagic fever patients in Malaysia. Clin Vaccine Immunol (2007) 1.06
Lymphocyte activation and hepatic cellular infiltration in immunocompetent mice infected by dengue virus. J Med Virol (2004) 1.04
Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol (2003) 1.04
Identification of cytolytic lymphocytes in West Nile virus-infected murine central nervous system. J Gen Virol (1989) 1.01
The primary in vivo murine cytotoxic T cell response to the flavivirus, West Nile. J Gen Virol (1987) 1.00
Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Gen Virol (1994) 0.99
Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol (1997) 0.98
Immune mediated and inherited defences against flaviviruses. Clin Diagn Virol (1998) 0.97
Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 non-structural protein. J Gen Virol (1998) 0.91
Recognition of helper T cell epitopes in envelope (E) glycoprotein of Japanese encephalitis, west Nile and Dengue viruses. Mol Immunol (1991) 0.90
Central nervous system infections in cancer patients. Semin Neurol (2004) 0.90
T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley encephalitis virus. J Virol (1991) 0.88
Antibody-dependent enhancement of tick-borne encephalitis virus infectivity. J Gen Virol (1985) 0.88
West Nile virus activity--United States, 2006. MMWR Morb Mortal Wkly Rep (2007) 0.87
Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol (1990) 0.87
Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J Gen Virol (1987) 0.86
Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing. Vaccine (2002) 0.85
Rodent models for the study of therapy against flavivirus infections. Antiviral Res (2004) 0.85
Assessment of the antigenic structure of tick-borne encephalitis virus by the use of synthetic peptides. J Gen Virol (1993) 0.85
Cytotoxic T lymphocytes raised against Japanese encephalitis virus: effector cell phenotype, target specificity and in vitro virus clearance. J Gen Virol (1994) 0.84
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
The immune epitope database 2.0. Nucleic Acids Res (2009) 6.07
Modeling biomedical experimental processes with OBI. J Biomed Semantics (2010) 5.36
Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol (2003) 4.64
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol (2006) 4.52
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
A community resource benchmarking predictions of peptide binding to MHC-I molecules. PLoS Comput Biol (2006) 3.73
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol (2008) 3.71
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
HLA class I supertypes: a revised and updated classification. BMC Immunol (2008) 3.47
Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med (2004) 3.43
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications. Immunogenetics (2005) 2.99
Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics (2005) 2.91
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A (2007) 2.67
Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics (2010) 2.53
Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol (2008) 2.48
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity (2008) 2.43
Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A (2008) 2.43
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
A roadmap for the immunomics of category A-C pathogens. Immunity (2005) 2.36
Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 2.32
ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics (2008) 2.26
Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol (2008) 2.25
Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol (2004) 2.21
Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 2.18
Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res (2008) 2.14
HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci U S A (2005) 2.11
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Immune epitope database analysis resource. Nucleic Acids Res (2012) 2.09
Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol (2008) 2.07
Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res (2008) 2.07
Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit (2007) 2.02
A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 1.98
Characterization of the peptide-binding specificity of Mamu-B*17 and identification of Mamu-B*17-restricted epitopes derived from simian immunodeficiency virus proteins. J Immunol (2002) 1.97
Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet (2005) 1.93
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A (2012) 1.89
Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med (2007) 1.82
Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition. J Immunol (2004) 1.81
Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog (2007) 1.78
Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77
The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus. J Virol (2007) 1.77
Automating document classification for the Immune Epitope Database. BMC Bioinformatics (2007) 1.76
Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J Immunol (2010) 1.76
HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol (2005) 1.75
Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol (2013) 1.71
Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules. Bioinformatics (2003) 1.71
Changing immunodominance patterns in antiviral CD8 T-cell responses after loss of epitope presentation or chronic antigenic stimulation. Virology (2003) 1.69
Transcatheter therapy of long extreme subatretic aortic coarctations with covered stents. Catheter Cardiovasc Interv (2004) 1.68
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics (2011) 1.68
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. J Immunol (2007) 1.66
Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol (2006) 1.66
Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine (2010) 1.61
Integrating epitope data into the emerging web of biomedical knowledge resources. Nat Rev Immunol (2007) 1.59
Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol (2005) 1.59